Atea Pharmaceuticals
Drug development and COVID 19 issues involving FDA, DOD, HHS, and OWS
Based in MA
AI Overview
With $160K in lobbying spend across 18 quarterly filings, Atea Pharmaceuticals is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2024.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $60K |
| 2021 | $70K |
| 2022 | $30K |
| 2023 | $0 |
| 2024 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Atea Pharmaceuticals disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Covid-19 Drug development involving DOD, HHS, FDA, and OWS
Drug Development for COVID
Covid treatment issues
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.